{
    "nct_id": "NCT05393921",
    "official_title": "The Clinical Efficacy of Intravesical Botox Injections When Combined with HoLEP Surgery in Patients with Benign Prostatic Hyperplasia and Overactive Bladder",
    "inclusion_criteria": "* Males age > 40\n* Patients diagnosed with Benign Prostatic Hyperplasia (BPH) and referred for HoLEP surgery\n* Lower urinary tract symptoms (LUTS) of Overactive Bladder Syndrome (OABS) frequency - urgency - urge incontinence episodes - dysuria - nocturia and eligible for bladder botox injections\n* International Prostate Symptom Score (IPSS) ≥ 17\n* Overactive Bladder Symptom Score (OABSS) ≥ 7\n* Participants have failed, are intolerant, or bad candidates for anticholinergic medication treatment for OAB\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 40 Years",
    "exclusion_criteria": "* History of bladder/prostate cancer\n* History of pelvic radiotherapy\n* History of neurological diseases\n* Presence of active Urinary Tract Infection (UTI)\n* Previous Bladder Outlet Procedure (Transurethral resection of prostate (TURP) Transurethral Incision of Prostate (TUIP) - UroLift, etc..)\n* History of adverse reaction to Botox injections\n* Post-void residual (PVR) greater than 300 ml\n* History of clean intermittent catheterization\n* Patients unable to stop anticoagulation of antiplatelet inhibitors 3 days prior to procedure",
    "miscellaneous_criteria": ""
}